Home > EADV Highlights
    • FILTER YOUR SEARCH
    Speciality:
    More Specialities

    • EADV Highlights

    Dermatological Conditions
    Esther van Zuuren, EADV 2021: Rosacea Classification

    It was a pleasure to be able to catch up with Dr Esther van Zuuren (Leiden University Medical Centre, Leiden, the Netherlands) to discuss rosacea classification and how this can impact treatment choices. Her presentation entitled ‘Update on topical drugs in rosacea‘ was received at the EADV Spring Symposium, 6-7 May 2021. Questions Could you […]

    Psoriasis
    Tiago Torres, EADV Spring Symposium 2021: Psoriasis Session Highlights

    It was a pleasure to discuss with Prof. Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) his highlights from the psoriasis session he chaired at the EADV Spring Symposium, 6-7 May 2021. Questions Could you give us a brief overview of the presentations on the psoriasis session that you chaired at EADV? (0:18) How has […]

    Psoriasis
    Tiago Torres, EADV Spring Symposium 2021: Comorbidities in Psoriasis

    We were delighted to speak with our Expert Faculty member, Prof. Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal), about the need to look for comorbidities in psoriasis. His talk entitled ‘Is there a need to look for comorbidities in psoriasis?’ was presented at the EADV Spring Symposium, 6-7 May 2021. Questions What cardiometabolic comorbidities […]

    Atopic Dermatitis
    Nives Pustišek, EADV Spring Symposium 2021: Treatment Goals in Atopic Dermatitis

    Following her presentation, we caught up with Dr Nives Pustišek (Children’s Hospital Zagreb, Croatia) to discuss current treatment goals in atopic dermatitis. Her talk entitled ‘Treatment strategies in 2021: Atopic Dermatitis’ was presented at the EADV Spring Symposium, 6-7 May 2021. Disclosures: Dr Nives Pustišek has nothing to disclose in relation to this video interview. […]

    Atopic Dermatitis
    Nives Pustišek, EADV Spring Symposium 2021: Current Treatment Strategies in Atopic Dermatitis

    We were delighted to speak with Dr Nives Pustišek (Children’s Hospital Zagreb, Croatia) about current treatment strategies in atopic dermatitis. Her talk entitled ‘Treatment strategies in 2021: Atopic Dermatitis’ was presented at the EADV Spring Symposium, 6-7 May 2021. Questions What are the keys to success with topical anti-inflammatory treatment? (0:15) What are the pros […]

    Psoriasis
    Lynda Grine, EADV Spring Symposium 2021: Intermittent Fasting in Psoriasis

    It was a pleasure to speak with Dr Lynda Grine (Ghent University Hospital, Ghent, Belgium) about her research into the effects of intermittent fasting on psoriasis. Her presentation entitled ‘Interim results of the MANGO trial: effects of modified intermittent fasting in psoriasis’ was presented at the EADV Spring Symposium, 6-7 May 2021. Questions Could you […]

    Psoriasis
    Linda Stein Gold, EADV Spring 2021: Roflumilast DERMIS-1 and DERMIS-2 Trials

    TouchIMMUNOLOGY got the opportunity to catch up with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, US) around the use of roflumilast in the treatment of chronic plaque psoriasis patients (Clinical Trial Identifier: NCT04211363 & NCT04211389). The abstract ‘Roflumilast cream, a once-daily, potent phosphodiesterase-4 inhibitor, in chronic plaque psoriasis patients: Efficacy and safety […]

    Dermatological Conditions
    Martin Metz, EADV 2020 – Ligelizumab in Chronic Spontaneous Urticaria

    It was a delight to be able to discuss with Martin Metz (Charité – Universitätsmedizin Berlin, Berlin, Germany) the results of the 52-week extension study (NCT02649218), which investigated the monoclonal anti-IgE antibody, ligelizumab, in patients who had not achieved complete urticaria activity control with omalizumab. His abstract entitled ‘Efficacy of ligelizumab in chronic spontaneous urticaria […]

    Psoriasis
    Diamant Thaçi, EADV 2020: Long-term Efficacy of Tildrakizumab in Psoriasis

    It was an honour to talk with Prof. Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754).  Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled […]

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72